These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31818959)

  • 1. Profiles of Local and Systemic Inflammation in the Outcome of Treatment of Human Cutaneous Leishmaniasis Caused by
    Navas A; Fernández O; Gallego-Marín C; Castro MDM; Rosales-Chilama M; Murillo J; Cossio A; McMahon-Pratt D; Saravia NG; Gómez MA
    Infect Immun; 2020 Feb; 88(3):. PubMed ID: 31818959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ex vivo host and parasite response to antileishmanial drugs and immunomodulators.
    Gonzalez-Fajardo L; Fernández OL; McMahon-Pratt D; Saravia NG
    PLoS Negl Trop Dis; 2015 May; 9(5):e0003820. PubMed ID: 26024228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immuno-pharmacokinetics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis Caused by Leishmania (Viannia).
    Gómez MA; Navas A; Prieto MD; Giraldo-Parra L; Cossio A; Alexander N; Gore Saravia N
    Clin Infect Dis; 2021 May; 72(10):e484-e492. PubMed ID: 32818964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural resistance to meglumine antimoniate is associated with treatment failure in cutaneous leishmaniasis caused by Leishmania (Viannia) panamensis.
    Fernández OL; Rosales-Chilama M; Sánchez-Hidalgo A; Gómez P; Rebellón-Sánchez DE; Regli IB; Díaz-Varela M; Tacchini-Cottier F; Saravia NG
    PLoS Negl Trop Dis; 2024 May; 18(5):e0012156. PubMed ID: 38709850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Host's immune response in unresponsive and responsive patients with anthroponotic cutaneous leishmaniasis treated by meglumine antimoniate: A case-control study of Th1 and Th2 pathways.
    Bamorovat M; Sharifi I; Aflatoonian MR; Sadeghi B; Shafiian A; Oliaee RT; Keyhani A; Afshar AA; Khosravi A; Mostafavi M; Parizi MH; Khatami M; Arefinia N
    Int Immunopharmacol; 2019 Apr; 69():321-327. PubMed ID: 30771740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profiling gene expression of antimony response genes in Leishmania (Viannia) panamensis and infected macrophages and its relationship with drug susceptibility.
    Barrera MC; Rojas LJ; Weiss A; Fernandez O; McMahon-Pratt D; Saravia NG; Gomez MA
    Acta Trop; 2017 Dec; 176():355-363. PubMed ID: 28843396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance of
    Regli IB; Fernández OL; Martínez-Salazar B; Gómez MA; Saravia NG; Tacchini-Cottier F
    Front Immunol; 2018; 9():3040. PubMed ID: 30622537
    [No Abstract]   [Full Text] [Related]  

  • 8. American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment.
    Carvalho SH; Frézard F; Pereira NP; Moura AS; Ramos LMQC; Carvalho GB; Rocha MOC
    Trop Med Int Health; 2019 Apr; 24(4):380-391. PubMed ID: 30681239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leishmania panamensis infection and antimonial drugs modulate expression of macrophage drug transporters and metabolizing enzymes: impact on intracellular parasite survival.
    Gómez MA; Navas A; Márquez R; Rojas LJ; Vargas DA; Blanco VM; Koren R; Zilberstein D; Saravia NG
    J Antimicrob Chemother; 2014 Jan; 69(1):139-49. PubMed ID: 23975742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacometabolomics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis.
    Vargas DA; Prieto MD; Martínez-Valencia AJ; Cossio A; Burgess KEV; Burchmore RJS; Gómez MA
    Front Pharmacol; 2019; 10():657. PubMed ID: 31281253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment by adding thalidomide to meglumine antimoniate in a case of refractory anthroponotic mucocutaneous leishmaniasis.
    Goyonlo VM; Vahabi-Amlashi S; Taghavi F
    Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():177-179. PubMed ID: 31492621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis resistant to meglumine antimoniate, but with good response to pentamidine: a case report.
    Pimentel MI; Baptista C; Rubin EF; Vasconcellos Ede C; Lyra MR; Salgueiro Mde M; Saheki MN; Rosalino CM; Madeira Mde F; Silva AF; Confort EM; Schubach Ade O
    Rev Soc Bras Med Trop; 2011; 44(2):254-6. PubMed ID: 21552747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate.
    Romero GA; Guerra MV; Paes MG; Macêdo VO
    Am J Trop Med Hyg; 2001 Nov; 65(5):456-65. PubMed ID: 11716098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotypic profiles of Leishmania (Viannia) braziliensis strains from cutaneous leishmaniasis patients and their relationship with the response to meglumine antimoniate treatment: a pilot study.
    Gagini T; de Oliveira Schubach A; de Fatima Madeira M; Maria Valete-Rosalino C; Fernandes Pimentel MI; da Silva Pacheco R
    Parasite; 2017; 24():34. PubMed ID: 28959938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial.
    Machado PRL; Ribeiro CS; França-Costa J; Dourado MEF; Trinconi CT; Yokoyama-Yasunaka JKU; Malta-Santos H; Borges VM; Carvalho EM; Uliana SRB
    Trop Med Int Health; 2018 Sep; 23(9):936-942. PubMed ID: 29924907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Leukocyte Responses in
    Gomez MA; Belew AT; Navas A; Rosales-Chilama M; Murillo J; Dillon LAL; Alexander TA; Martinez-Valencia A; El-Sayed NM
    Front Cell Infect Microbiol; 2021; 11():687607. PubMed ID: 34557423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous occurrence of cutaneous and mucocutaneous leishmaniasis caused by different genotypes of Leishmania (Viannia) braziliensis.
    Hoyos CL; Quipildor M; Bracamonte E; Lauthier JJ; Cajal P; Uncos A; Korenaga M; Hashiguchi Y; Barroso PA; Marco JD
    J Dermatol; 2019 Sep; 46(9):e320-e322. PubMed ID: 30938461
    [No Abstract]   [Full Text] [Related]  

  • 18. Chronicity of dermal leishmaniasis caused by Leishmania panamensis is associated with parasite-mediated induction of chemokine gene expression.
    Navas A; Vargas DA; Freudzon M; McMahon-Pratt D; Saravia NG; Gómez MA
    Infect Immun; 2014 Jul; 82(7):2872-80. PubMed ID: 24752514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate.
    Carrió J; Portús M
    BMC Pharmacol; 2002 May; 2():11. PubMed ID: 12019027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local Delivery of the Toll-Like Receptor 9 Ligand CpG Downregulates Host Immune and Inflammatory Responses, Ameliorating Established Leishmania (Viannia) panamensis Chronic Infection.
    Ehrlich AK; Fernández OL; Rodriguez-Pinto D; Castilho TM; Corral Caridad MJ; Goldsmith-Pestana K; Saravia NG; McMahon-Pratt D
    Infect Immun; 2017 Mar; 85(3):. PubMed ID: 28052994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.